Actively Recruiting
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
Led by University Hospital, Bordeaux · Updated on 2025-08-06
70
Participants Needed
1
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Graft versus Host Disease (GVHD) is frequent after allogeneic stem cell transplantation (alloSCT). GVHD occurs following 2 patterns : acute GVHD (aGVHD) or chronic GVHD (cGVHD). The latter occurs in nearly 50% of patients and its pathogenesis remains poorly understood. Previous translational studies have delineated biological immune dysregulation involved in cGVHD and facilitated the development of new drug and therapeutic strategies. New aspects of T and B cells collaboration in the context of cGVHD using blood description of a key player called TFH, classicaly involved in germinal center reaction, were previously uncovered (Forcade et al, Blood 2016). Previous studies in the context of auto-immune inflammation (lupus nephritis) or organ transplant rejection, suggested that target tissue could contain accessory lymphoid structures (TLS). The description of such structures in cGVHD target tissue would give the opportunity to directly analyze immune key player involved the pathogenesis of cGVHD.
CONDITIONS
Official Title
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 18 years old
- Have undergone an allogeneic stem cell transplant
- Have evidence of primary chronic GVHD or GVHD occurring after Donor Lymphocyte Infusion
- In first occurrence of cGVHD, no new systemic therapy started
- In recurrent cGVHD, steroid dose below 15mg/day of Prednisone
- Have read, understood, and signed informed consent for the study
- Have social security affiliation
You will not qualify if you...
- Patient under 18 years old or unable to give consent
- Using systemic steroids over 15mg/day of Prednisone or other systemic agents started in the last month
- Anticipated bleeding risk from biopsy
- Do not agree to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire
Pessac, France
Actively Recruiting
Research Team
E
Edouard FORCADE
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here